London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study ...
The FDA has accepted for review the BLA for mepolizumab as an add-on maintenance treatment for eosinophilic COPD.
Zacks.com on MSN13h
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & MoreIt was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news ...
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its ...
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.
TD Cowen analyst Steve Scala maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of $45.00. The ...
London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...
Last night, the Food and Drug Administration (FDA) sent a proposed rule to the White House Office on Management and Budget regarding nicotine levels in some tobacco products. The American Lung Associa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback